Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methylnaltrexone Bromide

FDA-approved product (solution, subcutaneous), marketed as Methylnaltrexone Bromide, Relistor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Methylnaltrexone Bromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Constipation
  • Opioid dependence

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Peripheral opioid receptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Methylnaltrexone Bromide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methylnaltrexone Bromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

    NCT06162377 · start 2024-01-10

    Registered record
    Registry ID
    NCT06162377
    Conditions
    Head and Neck Squamous Cell Carcinoma
    Interventions
    Methylnaltrexone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-01-10
    Completion
    2026-12-31
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Squamous Cell Carcinoma
    InterventionMethylnaltrexone
    PhasePhase 4
    Registry statusRecruiting

  • Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

    NCT04787848 · start 2021-11-15

    Registered record
    Registry ID
    NCT04787848
    Conditions
    Chronic Widespread Pain
    Interventions
    Relistor Injectable Product
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2021-11-15
    Completion
    2027-05-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Widespread Pain
    InterventionRelistor Injectable Product
    PhaseNot applicable
    Registry statusRecruiting

  • Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

    NCT03523520 · start 2020-12-23

    Registered record
    Registry ID
    NCT03523520
    Conditions
    Constipation Drug Induced
    Interventions
    Methylnaltrexone Bromide 150 mg Oral Tablet; Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1; Naloxegol 25 MG Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-12-23
    Completion
    2023-03-31
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation Drug Induced
    InterventionMethylnaltrexone Bromide 150 mg Oral Tablet; Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1; Naloxegol 25 MG Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

    NCT04151719 · start 2020-02-03

    Registered record
    Registry ID
    NCT04151719
    Conditions
    Pancreatic Cancer
    Interventions
    Methylnaltrexone bromide (MNTX)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2020-02-03
    Completion
    2024-02-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionMethylnaltrexone bromide (MNTX)
    PhasePhase 3
    Registry statusWithdrawn

  • A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

    NCT04083651 · start 2020-01-06

    Registered record
    Registry ID
    NCT04083651
    Conditions
    Pancreatic Cancer
    Interventions
    Methylnaltrexone bromide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2020-01-06
    Completion
    2023-10-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionMethylnaltrexone bromide; Placebo
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume

    NCT03283020 · start 2017-11-11

    Registered record
    Registry ID
    NCT03283020
    Conditions
    Pharyngeal Dysfunction; Pharyngeal Swallowing
    Interventions
    RemifentanilMNTX; PlaceboMNTX
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-11-11
    Completion
    2018-04-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharyngeal Dysfunction; Pharyngeal Swallowing
    InterventionRemifentanilMNTX; PlaceboMNTX
    PhasePhase 4
    Registry statusUnknown

  • Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

    NCT02977286 · start 2017-01-01

    Registered record
    Registry ID
    NCT02977286
    Conditions
    Constipation
    Interventions
    Naloxegol Oral Tablet; Placebo Oral Tablet; Docusate Sodium 100 Mg oral capsule [Colace]; Senna 217 Mg Oral Tablet; Polyethylene Glycols; Bisacodyl 10 mg Suppository; Magnesium Citrate Oral Liquid Product; Methylnaltrexone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-01-01
    Completion
    2019-10-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionNaloxegol Oral Tablet; Placebo Oral Tablet; Docusate Sodium 100 Mg oral capsule [Colace]; Senna 217 Mg Oral Tablet +4 more
    PhasePhase 4
    Registry statusTerminated

  • Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients

    NCT02942550 · start 2016-11

    Registered record
    Registry ID
    NCT02942550
    Conditions
    STEMI; Morphine; Ticagrelor; Methylnaltrexone
    Interventions
    Methylnaltrexone bromide (Relistor®).; Sodium Chloride 9mg/mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-11
    Completion
    2017-12
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSTEMI; Morphine; Ticagrelor; Methylnaltrexone
    InterventionMethylnaltrexone bromide (Relistor®).; Sodium Chloride 9mg/mL
    PhasePhase 4
    Registry statusCompleted

  • Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

    NCT02403830 · start 2015-08

    Registered record
    Registry ID
    NCT02403830
    Conditions
    Coronary Artery Disease
    Interventions
    Methylnaltrexone; Placebo; Morphine; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-08
    Completion
    2016-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionMethylnaltrexone; Placebo; Morphine; Ticagrelor
    PhasePhase 4
    Registry statusCompleted

  • Study of Methylnaltrexone in Opioid-Induced Constipation Patients

    NCT02574819 · start 2015-04

    Registered record
    Registry ID
    NCT02574819
    Conditions
    Opioid-induced Constipation
    Interventions
    Methylnaltrexone (MNTX); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2017-04
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-induced Constipation
    InterventionMethylnaltrexone (MNTX); Placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients

    NCT01889290 · start 2014-02

    Registered record
    Registry ID
    NCT01889290
    Conditions
    Opioid Use, Unspecified With Other Opioid-induced Disorder
    Interventions
    Methylnaltrexone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02
    Completion
    2016-06
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use, Unspecified With Other Opioid-induced Disorder
    InterventionMethylnaltrexone
    PhasePhase 1
    Registry statusCompleted

  • The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health

    NCT03014843 · start 2013-10

    Registered record
    Registry ID
    NCT03014843
    Conditions
    Endogenous and Esophageal Sensitivity
    Interventions
    Naloxone; Methylnaltrexone Bromide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndogenous and Esophageal Sensitivity
    InterventionNaloxone; Methylnaltrexone Bromide; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Methylnaltrexone Use for Opioid-induced Postoperative Constipation

    NCT01773096 · start 2013-05

    Registered record
    Registry ID
    NCT01773096
    Conditions
    Constipation
    Interventions
    Methylnaltrexone; Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-05
    Completion
    2015-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionMethylnaltrexone; Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
    PhasePhase 4
    Registry statusCompleted

  • Methylnaltrexone for Opioid Induced Constipation

    NCT01955213 · start 2012-07

    Registered record
    Registry ID
    NCT01955213
    Conditions
    Constipation
    Interventions
    methylnaltrexone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2012-07
    Completion
    2017-09
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    Interventionmethylnaltrexone
    PhaseNot recorded
    Registry statusTerminated

  • Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.

    NCT01596764 · start 2011-05

    Registered record
    Registry ID
    NCT01596764
    Conditions
    Intestinal Obstruction
    Interventions
    Loperamide placebo; Loperamide; Colon Transit; Sulfasalazine; Placebo of MNTX and NLX; Naloxone; Methylnaltrexone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Obstruction
    InterventionLoperamide placebo; Loperamide; Colon Transit; Sulfasalazine +3 more
    PhasePhase 1
    Registry statusCompleted